Dr. Connor Frey Interview on GLP-1 RAs and Menstrual Signals

A new interview with Connor Frey, MD, explores the potential link between GLP-1 receptor agonists and menstrual adverse event signals. The discussion, published in July 2026, sheds light on clinical observations and data analysis. Dr. Frey provides insights into how these medications may affect…

Interview Overview

A detailed question-and-answer session with Connor Frey, MD, was published on July 21, 2026, covering the topic of GLP-1 receptor agonists and reports of menstrual adverse events. The interview focuses on emerging signals that some patients using GLP-1 RAs may experience changes in their menstrual cycles. Dr. Frey, a medical doctor, discusses the clinical significance of these observations and the need for further investigation.

GLP-1 receptor agonists are a class of medications commonly prescribed for type 2 diabetes and more recently for weight management. As their use expands, adverse event surveillance becomes increasingly important. The interview addresses specific menstrual-related events that have been reported, including timing, severity, and patterns.

Menstrual Adverse Event Signals

During the interview, Dr. Frey examines data from clinical trials and post-marketing reports that suggest a possible association between GLP-1 RAs and menstrual irregularities. The discussion notes that while these signals are not yet definitive, they warrant careful monitoring by healthcare providers. The exact mechanisms linking GLP-1 receptor activity to menstrual function remain under study.

The interview highlights the importance of differentiating between direct drug effects and indirect influences, such as weight loss or metabolic changes. Dr. Frey emphasizes that clinicians should ask patients about menstrual history before and during treatment. The signals include reports of delayed menstruation, changes in flow, and intermenstrual bleeding, though no specific statistical figures are cited in the interview.

Clinical Implications

Given the increasing number of patients prescribed GLP-1 RAs, understanding potential reproductive side effects is crucial. Dr. Frey advises that healthcare professionals remain vigilant and report any adverse events to regulatory databases. The interview does not conclude a causal relationship but calls for more targeted studies to clarify the association.

The Q+A format allows for direct questioning about how to counsel patients who experience menstrual changes. Dr. Frey recommends a thorough evaluation to rule out other causes, such as pregnancy, hormonal disorders, or concurrent medications. The discussion reinforces that shared decision-making should include awareness of possible menstrual effects.

Overall, the interview with Connor Frey, MD, serves as a timely resource for clinicians managing patients on GLP-1 receptor agonists. It underscores the need for ongoing pharmacovigilance as the therapeutic landscape evolves. The full Q+A provides additional context on data sources, patient demographics, and future research directions.

Peptides referenced: GLP-1.